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A relative immunosuppression is observed in patients
after sepsis, trauma, burns, or any severe insults. It is
currently proposed that selected patients will benefit
from treatment aimed at boosting their immune
systems. However, the host immune response needs to
be considered in context with pathogen-type, timing,
and mainly tissue specificity. Indeed, the immune status
of leukocytes is not universally decreased and their
activated status in tissues contributes to organ failure.
Accordingly, any new immune-stimulatory therapeutic
intervention should take into consideration potentially
deleterious effects in some situations.Arbitrarily classifying cytokines as pro- or
Introduction
Refinements of supportive care of patients with severe sep-
sis have decreased their overall mortality, but no adjuvant
drug therapy has emerged despite strenuous efforts in the
field. Twenty years have passed since the first patients with
sepsis were included in clinical trials based on the under-
standing that TNF orchestrates the inflammatory response
and should be the target for therapeutic intervention. In re-
sponse to the failure of therapies aiming to target either
the up-stream microbial activators or the effector mole-
cules of the inflammatory cascade, a new concept has
emerged of boosting the immune system to counter im-
munosuppression that develops in patients who survive
the initial, hyperinflammatory period of sepsis [1].
Inflammation is a highly sophisticated and complex re-
sponse that fundamentally ‘aims’ to protect the host. In
this review, we argue against the promulgation of what
we believe is a misleading perception of sepsis inducing
secondary immunosuppression. The possible negative
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2014so great that we believe such an approach should be
considered with great caution.
It is important to realize that events occurring in patients
with sepsis are not a simple dichotomy resulting from a
balance between pro-inflammatory and anti-inflammatory
mediators. Oversimplification may have led to previous
therapeutic failures. Maintaining such an over-simplistic
analysis of inflammation may lead to further failed trials,
compounding our current state of therapeutic futility in
sepsis. By reviewing the immunological events of sepsis, we
also attempt to understand why we have already spent over
20 fruitless years trying to reverse it with targeted adjuvant
therapies.anti-inflammatory mediators is unreliable
Classifying cytokines as pro- or anti-inflammatory has led
to oversimplification of the inflammatory response. Con-
sequentially, especially in a disorder as complex as sepsis,
simplistic therapeutic approaches have been considered.
The inappropriateness of this classification is widely
illustrated by studies revealing some paradoxical behaviors
of so-called pro- and anti-inflammatory cytokines. In re-
gard to TNF, the prototypic ‘pro-inflammatory’ cytokine,
TNF-treated murine macrophages produced less IL-12
and IL-23 after IFNγ and lipopolysaccharide (LPS) stimu-
lation [2]. In vivo, TNF induces extra-adrenal production
of immunoregulatory glucocorticoids in the intestinal mu-
cosa during acute intestinal inflammation [3]. Similar ob-
servations have been reported for other pro-inflammatory
cytokines such as IL-1 and IFNγ. In a dextran sulphate
sodium-induced colitis model, mice deficient in IL-1RI
signaling showed increased susceptibility to and failed to
mount a protective type I interferon response after Toll-
like receptor (TLR) 9 ligand administration [4]. Further-
more, IFNγ knockout (KO) mice had significantly greater
endotoxin-induced uveitis as compared with wild-type
mice, and the injection of murine IFNγ suppressed the se-
verity of endotoxin-induced uveitis in both wild-type and
KO mice [5].al Ltd. The licensee has exclusive rights to distribute this article, in any medium,
this time, the article is available under the terms of the Creative Commons
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10, the prototypic anti-inflammatory cytokine. Its pro-
inflammatory activity been established in human volun-
teers receiving endotoxin injection [6]. Our own in vitro
studies showed that adherence of human monocytes
modulated the effect of IL-10 on expression of 16 genes,
including ‘suppressor of cytokine stimulation’ (SOCS)
molecules, in the opposite direction as compared with
non-adherent cells [7]. These observations illustrate the
statement by Moore and colleagues that ‘IL-10 can effect
very different outcomes depending on timing, dose, and
location of expression. In some scenarios, the expected
immuno-suppressive activities are observed, while in
others, IL-10 enhances immune or inflammatory re-
sponses’ [8].
Among other cytokines classified as anti-
inflammatory, transforming growth factor-beta (TGFβ)
may behave as pro-inflammatory mediator as TGFβ-
transgenic mice are more sensitive to LPS-induced
shock [9] and some of its inflammatory activities reflect
its capacity to favor the differentiation of T helper (Th)
17 and production of the pro-inflammatory IL-17. The
classification of non-cytokine inflammatory mediators
also relies on an overly simplistic division between pro-
and anti-inflammatory properties. This is well illustrated
by prostaglandin E2 (PGE2), a key mediator of infectious
immunopathology. On one hand, PGE2 induces fever, in-
creases vascular permeability, increases vasodilatation,
and causes pain while also inhibiting production of TNF,
increasing production of IL-6, inhibiting 5-lipoxygenase
and leukotriene A4 generation, and inducing 15-
lipoxygenase and the generation of the lipoxins involved
in inflammation resolution. On the other hand, PGE2
has inhibitory properties on macrophages, neutrophils,
Th1 lymphocytes, natural killer (NK) cells, and cytotoxic
lymphocytes but activates mast cells, Th2, Th17, and
regulatory T lymphocytes (Treg) [10]. This panoply of
PGE2-stimulated events amply demonstrates the inability
to simply characterize the activities of this and the other
molecules mentioned as pro- or anti-inflammatory.
Sometimes-ambiguous roles of cytokines in
infection and sepsis
In an early anti-TNF monoclonal antibody intervention
study, a significant improvement in day 3 survival was
observed between the antibody-treated group and the
placebo group [11]. Although this was not a pre-
specified primary outcome, it is interesting to see that
the treatment targeting TNF consisting of a single early
injection was beneficial within a short period of time
after sepsis onset, reinforcing the idea that TNF plays a
key deleterious role in the early events of sepsis. Once
anti-TNF treatments were better targeted to the sickest
patients by adding biological inclusion parameters(plasma IL-6 level), survival was significantly improved
on day 28 [12].
Synergistic effects between immune modulators are a
key characteristic of their effect. This explains how a
non-lethal dose of one cytokine can lead to mortality
when injected with a non-lethal dose of another cyto-
kine. Similarly, it may explain how the removal of some
inflammatory mediators by coupled plasma filtration-
adsorption was protective in an endotoxin-shock model
while levels of circulating bio-active TNF were un-
affected [13].
Clear demonstrations of cytokine-mediated tissue
damage exist. Nevertheless, because of their ambiguous
role mentioned above, identification of their precise role
during sepsis has led to controversy. In animal models
of sepsis, the role of TNF may vary depending upon the
type of infection [14]. Many model parameters influence
conclusions of the relative role of the different mediators
studied. Identical cytokines have been found to be pro-
tective or deleterious depending upon the model. This
has been the case for IFNγ [15] and granulocyte-
macrophage colony-stimulating factor (GM-CSF) [16]
among others (for example, IL-17, IL-33, ‘TNF-related
apoptosis-inducing ligand’ (TRAIL), and TGFβ).
Opposing effects of immune cells in sepsis
Host-protective innate immune responses and conse-
quent inflammation are inextricably linked and overlap-
ping. Consequently, the same cellular actors are key
elements defending the host against infection while sim-
ultaneously contributing to deleterious events. For ex-
ample, neutrophil extracellular traps that catch and kill
bacteria and fungi are associated with the release of ele-
ments such as histones and mitochondria that behave
like damage-associated molecular patterns perpetuating
the inflammatory process.
Beneficial or deleterious roles of the same leukocyte
subset have been reported depending upon the experi-
mental model. For example, a peritonitis model using
nude mice (lacking T cells) suggested that T lympho-
cytes contribute to protective immune responses [17].
By contrast, in an Escherichia coli sepsis murine model,
T lymphocytes markedly contributed to severity [18].
Similarly, Treg improved survival in polymicrobial sepsis
[19] whereas, in another report, reduced Treg activity led
to improved survival [20]. The ‘half angel/half devil’ role
of NK cells during severe infection is also described. NK
cells contribute to systemic inflammation during polymi-
crobial sepsis but play a critical protective role in host
defense against Staphylococcus aureus lung infection (as
reviewed in [21]). Although apoptosis of dendritic cells
(DCs) is particularly increased during sepsis, they are
protective in murine polymicrobial sepsis [22]. Tran-
scriptomic analysis of DCs in trauma patients shows a
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gesting their contribution to systemic inflammation and
organ failure [23].
Apoptosis of lymphocytes, DCs, and NK cells is a hall-
mark of sepsis. Hotchkiss and colleagues [24] provided
key experiments demonstrating that lymphocyte apoptosis
was deleterious and its prevention highly protective. In
addition to the depletion of apoptotic lymphocytes that
contribute to the alteration of the immune status, apop-
totic T cells themselves can further produce an immuno-
suppressive milieu following their release of TGFβ [25]. In
contrast, the apoptosis of neutrophils is reduced. Interest-
ingly, injection of apoptotic neutrophils in LPS-challenged
mice with or undergoing cecal ligature puncture improved
outcomes [26]. This may be due to the capacity of apop-
totic neutrophils to limit the production of IL-1 and TNF
by LPS-activated monocytes and to favor the production
of IL-10 and TGFβ [27]. Favoring neutrophil apoptosis
while differentially preventing that of lymphocytes and
DCs would represent a considerable interventional
challenge!
Inflammatory mediators and their effects in
various organ compartments promote organ
failure
In sepsis, apoptosis does not only affect immune cells.
Apoptosis of epithelial cells, endothelial cells, neurons, and
cardiac myocytes is reported with crucial effects of loss of
altered barrier function (Figure 1): in the lungs - acute lung
injury and adult respiratory response syndrome [28]; in the
kidneys - acute kidney injury [29]. Enhanced translocation
of bacteria and bacterial products occurs consequent onFigure 1 During sepsis, many types of cells (but not neutrophils) disp
consequences. AKI, acute kidney injury; ALI/ARDS, acute lung injury/acuteintestinal epithelial cell apoptosis [30], contributing to the
concept of the gut as the motor of multiple organ failure
(MOF). Sepsis-induced cardiac myocyte apoptosis pro-
duces altered contractility and cardiac dysfunction [31].
Apoptosis of endothelial cells [32] induces vascular leakage.
Finally, microglial and neuronal apoptosis may follow auto-
nomic failure that precedes shock and MOF [33].
In addition to epithelial apoptosis, tight junction alter-
ations enhance organ dysfunction. It has been demon-
strated that nitric oxide favors disruption of epithelial cell
tight junctions in numerous organs, including liver, gut,
and lung. Leukotrienes favor protein extravasation as
shown in the kidney of septic mice [34].
Still, cytokines remain the main orchestrators of these
tissue injuries. In a model of acute kidney injury, it was
nicely demonstrated that inflammatory cytokines, in-
cluding TNF and IL-17, cause small intestine and liver
injury [35]. Among others, IL-17A is critical for gener-
ation of intestinal ischemia/reperfusion injury and subse-
quent liver and kidney injury [36]. All together, the
altered functions of epithelial cells, endothelial cells,
neurons, and cardiac myocytes contribute to MOF that
may influence outcomes in sepsis more than altered im-
mune status.
The concomitant occurrence of inflammation,
anti-infectious response, and altered immune
status in sepsis
When Roger Bone coined the concepts of systemic in-
flammatory response syndrome (SIRS) and compensa-
tory anti-inflammatory response syndrome (CARS), he
conceived that one or the other would be predominatinglay enhanced apoptosis, leading to various deleterious
respiratory distress syndrome; NK, natural killer.
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ered an adapted compartmentalized response with the
aim of silencing some acute pro-inflammatory genes and
maintaining the expression of certain genes involved in
the anti-infectious process. Despite our views [38], authors
still propose a two-wave concept with SIRS appearing be-
fore CARS, although they admit that ‘rigorous examin-
ation of previous studies provides evidence that both pro-
inflammatory and opposing anti-inflammatory response(s)
occur concomitantly in sepsis’ [1].
Tamayo and colleagues [39] studied a large panel of cir-
culating cytokines in patients with SIRS or sepsis, con-
cluding that both pro- and anti-inflammatory mediators
play roles from the very beginning of this life-threatening
condition. Similarly, meta-analysis of 12 transcriptomic
studies including 784 individuals led to the conclusion
that ‘the arbitrary distinction of separating sepsis into pro-
inflammatory and anti-inflammatory phases is not sup-
ported by gene-expression data’ [40].
Immune status has been studied frequently by measur-
ing TNF or other inflammatory cytokine production by
circulating monocytes in response to LPS [41]. We studied
patients undergoing abdominal aortic surgery, showing
that reduced expression of human leukocyte antigen
(HLA)-DR on CD14HIGH monocytes occurs during sur-
gery [42]. Similarly, HLA-DR expression was already re-
duced on monocytes taken very soon after severe trauma
at accident scenes [43]. Altered TNF production capacity
of circulating cells in response to TLR2 or TLR4 agonists
is also observed very soon after injurious insults, such as
on admission of patients after cardiac arrest [44]. Even if
soon after the initial insult the intensity of the inflamma-
tory response reaches its peak, there is a persistent inflam-
mation associated with altered immune status in surviving
patients [45]. The more severe the insult, the more pro-
found is the alteration and the more chance the patients
have to develop adverse clinical outcome.
The immune status of leukocytes during sepsis
and SIRS varies depending on the compartment
in which they reside
Terms such as ‘immunoparalysis, immunosuppression,
and anergy’ are far too extreme to describe the immune
status of circulating leukocytes in patients with sepsis or
SIRS. Altered immune status of circulating leukocytes is
not globally present. Indeed, some functions like phago-
cytosis remain unaltered [46], and ex vivo cytokine pro-
duction in response to heat-killed S. aureus (HKSA)
remains unchanged in patients with sepsis [47] com-
pared with healthy controls. This is in full agreement
with the observation that LPS primes HKSA-induced
TNF production in macrophage cell lines instead of
leading to cross-tolerance [48]. While the concept of
endotoxin tolerance is considered to partially mimic thealteration of immune status in sepsis, it is worth men-
tioning that cross-tolerance between microbial agonists
is not invariant. For example, Candida albicans and fun-
gal cell wall β-glucan also prime LPS-induced pro-
inflammatory cytokine production [49].
These observations led us to propose the concept of
leukocyte reprogramming [50] to explain the fact that
tolerised macrophages retain anti-infectious properties. In
addition, in tissues, there are numerous examples to illus-
trate the hyper-activity of these cells. For example, in mice
with polymicrobial sepsis alone or as a ‘second hit’ after
traumatic hemorrhage, it was nicely demonstrated by
Chaudry’s group [51] that the ex vivo production of TNF
or IL-6 after LPS activation was significantly reduced
among peripheral blood mononuclear cells and splenic
macrophages but that it was enhanced in alveolar and
Kupffer cells. Similarly, in a murine model of trauma, the
cytokine productive capacity of Kupffer cells and alveolar
macrophages was enhanced [52]. Indeed, macrophage
functions differ depending on the compartment from
which they derive. We established [53] that the specific
cytokine and cellular microenvironment within the lung
was responsible for this particular resistance of alveolar
macrophages to endotoxin tolerance, which can also be
observed in human alveolar macrophages [54]. Similarly,
in kidneys, in response to a second challenge with LPS,
the expression of TNF and inducible nitric oxide synthase
was further enhanced [55]. This may explain why unilat-
eral nephrectomy could be protective in a murine periton-
itis model and after LPS injection [56]. Most importantly,
despite the fashionable concept of M1/M2 macrophages,
the response of macrophages to IL-4 and IFNγ is in fact
completely different depending upon their origin [57]. As
a consequence of this great heterogeneity of immune cells
within different compartments, each tissue behaves inde-
pendently, contributing to the global inflammatory re-
sponse with a specific pattern, as illustrated by differential
cytokine expression in liver, lungs, heart, brain, muscle,
kidney, intestine, and spleen [58]. Another example of the
different behavior of leukocytes in various compartments
is the frequent occurrence of hemophagocytosis (>60%)
directly observed in the bone marrow of the critically ill
[59]. This phenomenon is associated with extreme pro-
duction of inflammatory cytokines. Accordingly, it has
been proposed that when hemophagocytosis is diagnosed
in critical care patients, aggressive immunosuppressive
therapy be undertaken without delay [59].
Differences between cells harvested from different
compartments after sepsis have also been reported for
spleen and peritoneal myeloid DCs [60]. The major dif-
ferences between compartments are further illustrated
by the fact that gene deficiency may differentially affect
outcomes of infection. For example, IL-10 deficiency
protects against Francisella tularensis pulmonary
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larly, we showed that scavenger receptor-A (SR-A),
‘macrophage associated receptor with a collagenous
base’ (MARCO), CD36, or TLR2 deficiency protect mice
against peritoneal S. aureus infection while these defi-
ciencies aggravated pneumonia [62]. Interestingly, when
Streptococcus pneumoniae was the pathogen used to
colonize the murine nasopharynx, MARCO KO mice
(but not SR-A KO mice) had significantly impaired
clearance of pneumococcal colonization [63].
Furthermore, inflammatory foci cells may not behave
similarly to cells from other healthy compartments. For
example, it was shown that neutrophils derived from
sputum of patients with chronic bronchitis or cystic fi-
brosis are insensitive to inhibitory effects of IL-10 in
contrast to circulating neutrophils [64].
Murine models poorly mimic the clinical settings
The concomitant presence of inflammation within tissues
and altered immune status within the hematopoietic com-
partment is short-lived in murine models rendering them
inappropriate to study patients with concomitant sepsis
and CARS [65]. In addition, mice are highly resistant to
bacteria like S. aureus and their serum contains factors
that limit inflammatory response intensity as compared
with human serum [66]. A most provocative report com-
paring transcriptomic patterns of circulating cells from
trauma patients, human endotoxemia-model participants,
and murine-model equivalents revealed total absence of
correlation [67]. When most therapeutic approaches have
been validated in preclinical studies performed with mur-
ine models, one understands why those were not the most
appropriate ones.
The scientific community needs to reconsider models
used to validate therapeutic approaches. If murine re-
sponses do not resemble human processes, maybe other
species, like the pig, should be preferred. Porcine mono-
cytes and LPS-activated macrophages are closer to their
human counterparts than murine cells [68]. Of course,
murine models remain valuable to further decipher the
mechanisms of sepsis. The best example is the two-hit
model, which demonstrated that the nature of the first
hit and its severity, the nature of the infection, and the
route of infection may influence the outcome in a com-
pletely opposite direction [69].
Are patients with sepsis dying of immune
failure - dissecting the arguments used to
describe compensatory immunosuppression
occurring after sepsis?
The clinical observations used to argue that immuno-
suppression occurs in sepsis patients surviving the initial
inflammatory cascade [1] are in essence that patients
develop nosocomial infections due to opportunisticpathogens, including reactivated chronic viral infections,
and that patients who die after sepsis have unresolved
foci of infection. These underpinning observations re-
quire further consideration.
Representing bacteria such as Enterococcus faecium,
Stentrophomonas maltophilia, and Pseudomonas aerugi-
nosa along with Candida as ‘opportunistic pathogens’
overstates the role of sepsis-induced immune dysregula-
tion as the primary cause of nosocomial infection in these
patients. These multiply-instrumented, high-intensity care,
bed-bound, vulnerable patients often have breaches in
their integument and mucous membranes (airways, surgi-
cal sites, indwelling catheters) and perturbed microbiomes
from antibiotic treatments. Overgrowth of antibiotic-
resistant microorganisms and barrier defects predispose
them to secondary infections, even without overt defects
in their immune defenses [70]. These are all organisms of
normal virulence that cause nosocomial infections in sep-
sis patients because of the selection pressure of potent an-
tibiotics and the presence of biofilm affected/colonized
intravascular and urinary catheters.
Additionally, reactivation of herpes simplex virus (HSV)
and cytomegalovirus (CMV) may have some clinical rele-
vance in critically ill patients. CMV-emia is quite common
in patients with sepsis (30% in some studies) and is at least
associated with worse outcome in ICU patients in recent
meta-analyses. Whether CMV could cause immune com-
promise itself, be a reflection of immune compromise, or
simply be an indicator of poor outcome in patients with
sepsis remains unclear [71]. Reactivation of oro-labial
HSV is extremely common in sepsis, and HSV can fre-
quently be detected in respiratory secretions. However,
only one study has reliably investigated lower respiratory
tract infection in critically ill, immunocompetent patients,
showing that 21% of patients with ventilator-associated
pneumonia (VAP) had bronchopneumonitis due to HSV
[72]. In 55% of these patients, the VAP appeared to be due
to HSV alone. However, acyclovir treatment had no im-
pact on the outcome in patients with HSV bronchopneu-
monitis [72]. Of greater relevance to predisposition to
nosocomial infection in sepsis patients remaining in ICUs
for prolonged periods are physical breaches in innate im-
mune system barriers. Intravascular catheters, endo-
tracheal tubes with consequently increased dead space,
and increased gastric pH due to peptic ulcer prophylaxis
regimens are all, along with broad-spectrum antibiotics,
potent promoters of nosocomial infection.
Post-mortems (PMs) identifying unresolved infection
foci are not reliable proof that patients are dying of sep-
sis. Pneumonia is frequently present in patients in whom
supportive care is withdrawn due to failure to thrive.
Where pneumonia has been found more frequently at
PM than was appreciated ante-mortem, the extent of
pulmonary involvement was not quantified [73]. In this
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sessment that MOF was the commonest cause of death
[73]. These data call into question the relevance of unre-
solved, PM infection in patients dying in the ICU as a
direct indicator of immunosuppression following as a
direct consequence of previous sepsis. If the patients die
with infectious foci and altered immune status, it does
not mean they die because of them.
Boosting the immune system
Because of the monocyte deactivation in sepsis, it was
proposed to restore it with the use of either IFNγ or
GM-CSF, two cytokines that counteract endotoxin toler-
ance. The first attempt was successfully performed in
nine septic patients who received subcutaneous IFNγ
that restored ex vivo cytokine production and HLA-DR
expression by monocytes [74]. The authors claimed that
overall mortality was lower in the treated group com-
pared with historical controls. In mechanically ventilated
trauma patients, IFNγ was aerosolized. However, in a
previous phase III study in burn patients, IFNγ had
failed to protect patients from infection or decrease
mortality [75]. We must recall that IFNγ injection in-
creases mortality in animal models of polymicrobial in-
fection [15]. All together, these data have limited the
routine use of IFNγ in ICU patients, although a Dutch
clinical trial is ongoing.
GM-CSF has been demonstrated to be able to restore
some immune status parameters. However, a meta-
analysis concluded that GM-CSF did not significantly
reduce in-hospital mortality, although it significantly in-
creased infection recovery [76]. Although no adverse ef-
fects were reported, it is worth recalling a case report of
a patient who developed a fatal adult respiratory distress
syndrome after GM-CSF treatment [77]. In animal
models, GM-CSF favors LPS-induced lung inflamma-
tion, amplifying LPS-induced bronchoconstriction [78].
GM-CSF favors production of TNF and IL-1. In a recent
study, it was confirmed that GM-CSF synergizes with
LPS, promoting IL-1β secretion [79]. Lethal injection of
LPS in GM-CSF receptor KO mice led to far lower mor-
tality among these mice as compared to wild type mice.
Given all the efforts made by some authors to convince
the scientific community of the use of GM-CSF, it is
challenging to read the conclusion of this present paper
given that GM-CSF has been previously underestimated
as a target for therapeutic intervention in many bacterial
infections and inflammatory disorders associated with
the production of IL-1β.
IL-7 is another cytokine that is promoted for the treat-
ment of sepsis and that is supported by murine and hu-
man ex vivo tissue data [1,80]. One can conjecture that
systemic treatment with IL-7 may act in undesired
places, as illustrated by the following: IL-7 worsensgraft-versus-host-induced tissue inflammation [81]; favors
inflammation in colitis [82], contributes to arthritis sever-
ity [83]; upregulates chemokines, IFNγ, macrophage
recruitment, and lung inflammation [84]; and, finally, in-
creases production of inflammatory cytokines by mono-
cytes and T cells [85].
Many other cytokines (for example, IL-2, IL-12, IL-15,
and TNF) can boost the immune system and are reported
to be beneficial in murine sepsis models. However, one
wonders whether systemic treatment with any immunosti-
mulating cytokine may act on tissue leukocytes boosting
the inflammatory process while boosting immune status
as well. In this perspective, the attempt to treat peripheral
mononuclear cells of sepsis patients ex vivo with IL-2 be-
fore re-injecting them is an interesting approach that pre-
vents the delivery of this cytokine to the bloodstream,
allowing it to act strictly on the desired cells [86]. In this
study, the mortality was 8% in the extracorporeally treated
group of patients (n = 121) but was 21% in the patients re-
ceiving standard treatment (n = 52).
Approaches for innovative therapeutic
interventions
Rather than repeating the mistakes of past experimental
treatments for sepsis in which therapies were developed
after successful preclinical models that may be far from
mimicking human disease, it would be ideal to proceed
in the future with new treatments in which extensive hu-
man data are available prior to embarking on expensive
licensure studies. Furthermore, identifying currently li-
censed drugs with tolerable safety profiles as potential
sepsis agents leap-frogs costly drug development and
early-phase human studies.
In animal models, extant licensed drugs, such as chloro-
quine [87] and androstenenediol [51], have successfully re-
stored immune status. Most interestingly, in the latter
case, the treatment protected mice against polymicrobial
sepsis and boosted altered ex vivo cytokine production ob-
served with peripheral blood cells and spleen macro-
phages, dampening production observed with alveolar
macrophages and Kupffer cells. A similar compartmental-
ized adapted specificity was reported with estradiol [88].
Other approaches involve pro-resolving lipid mediators
[89], although it is uncertain whether they may also ad-
versely boost immune status. The recently recognized
aspirin-triggered lipoxins, anti-inflammatory mediators of
inflammation resolution, make aspirin a possible inexpen-
sive agent for both prevention and treatment of sepsis.
Considerable observational cohort data show improve-
ments in mortality in patients with sepsis pretreated with
aspirin [90]. This approach is being prospectively studied
as part of an aspirin primary prevention trial.
Could other immunomodulatory approaches be con-
sidered with less putative dangerous consequences on
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Indeed, a very promising study demonstrated its effi-
ciency to improve clinical outcome in patients with se-
vere sepsis [91], after a preliminary investigation had
demonstrated a better performance with respect to
organ failure scores in thymosin-α1-treated patients with
sepsis arising from intra-abdominal infection due to
carbapenem-resistant bacteria [92]. However, one must
call for caution since thymosin-α1 can also favor the
production of inflammatory cytokines and nitric oxide
and further increases the percentage of Treg cells [93,94].
Still, very little is known of its effect on leukocytes
present in different compartments.
The cell surface molecules containing in their intracy-
toplasmic domain an immunoreceptor tyrosine-based
inhibition motif - such as programmed death-1 (PD-1),
B and T lymphocyte attenuator (BTLA), and cytotoxic
T-lymphocyte antigen 4 (CTLA-4) - could also be inter-
esting targets for new therapeutic approaches. The ex-
pression of PD-1 on T cells and its ligand (PD-L1) on
monocytes is upregulated in critically ill [95] or septic
shock [96] patients. Increased expressions were associ-
ated with increased occurrence of secondary nosocomial
infections and mortality after septic shock [97]. Not only
are PD-1-deficient mice markedly protected from the le-
thality of sepsis, accompanied by a decreased bacterial
burden and suppressed inflammatory cytokine response
[98], but also blockade of PD-1 or PD-L1 improves sur-
vival in a murine model of sepsis, reverses immune dys-
function, inhibits lymphocyte apoptosis, and attenuates
organ dysfunction [99-101]. The relevance of these ob-
servations in human settings is still needed. CTLA-4 is aFigure 2 New therapeutic interventions should address both the even
immune status of leukocytes restricted to some specific compartmenhigh-avidity receptor for CD80 and CD86. Enhanced
CTLA-4 expression was demonstrated more frequently
in patients with sepsis than in non-infected critically ill
patients or control subjects [102], and blocking CTLA-4
improved survival in bacterial and fungal experimental
sepsis [103,104]. However, the use of such an approach
seems tricky since, in animal models at high dose, anti-
CTLA-4 could worsen survival [103], and the use of
Abatacept (a soluble CTLA-4 dimerized with an Fc frag-
ment of immunoglobulin) led to increased survival in in-
vasive pneumococcal infection [105]. Similarly, BTLA
expression is enhanced in patients with SIRS or sepsis
[106] and, in a murine model of sepsis, BTLA-deficient
mice displayed an enhanced resistance [107]. In contrast,
these mice displayed enhanced susceptibility to
endotoxin-induced shock [108]. Accordingly, the exact
role of BTLA needs to be further deciphered before
strategies targeting BTLA could be proposed to treat pa-
tients with sepsis.
Conclusions
New therapeutic approaches to treat sepsis should take
into consideration that the immune status of leukocytes in
the peripheral blood might be quite different from those
present in inflamed tissues. We believe that a systemic ap-
proach to immune stimulation is not appropriate if im-
mune cells are boosted generally, independent of their
location. An ideal drug would limit the overzealous in-
flammatory process that leads to organ failure and favor
homeostatic responsiveness of leukocytes (Figure 2). This
is the challenge we have to address if we wish to avoid
further decades of disillusionment.ts in the tissues that lead to organ failure and the altered
ts.
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PGE2: Prostaglandin E2; PM: Post-mortem; SIRS: Systemic inflammatory response
syndrome; SR-A: Scavenger receptor-A; TGFβ: Transforming growth factor-beta;
Th: T helper; TLR: Toll-like receptor; TNF: Tumor necrosis factor; Treg: Regulatory T
lymphocyte; VAP: Ventilator-associated pneumonia.
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